Sign Up Today and Learn More About MycoMedica Life Sciences, PBC Stock
Invest in or calculate the value of your shares in MycoMedica Life Sciences, PBC or other pre-IPO companies through EquityZen's platform.
MycoMedica Life Sciences, PBC Stock (MLSP)
Psychedelic Medicines
About MycoMedica Life Sciences, PBC Stock
Founded
2021
Headquarters
Shelton, WA, US
Industries
Software, Artificial Intelligence, Data and Analytics
MycoMedica Life Sciences, PBC Press Mentions
Stay in the know about the latest news on MycoMedica Life Sciences, PBC
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024
biospace • Apr 01, 2025
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
businesswire • Nov 15, 2024
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
benzinga • Nov 12, 2024
MycoMedica Life Sciences Secures $60 Million in Funding
finsmes • Jun 03, 2022
MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders
globenewswire • Jun 01, 2022
MycoMedica Life Sciences, PBC Management
Leadership team at MycoMedica Life Sciences, PBC
Co-founder & Managing Director, Obvious Ventures
James Joaquin
Co-Founder and Chief Executive Officer
Paul Stamets
Join now and verify your accreditation status to gain access to:
- MycoMedica Life Sciences, PBC Current Valuation
- MycoMedica Life Sciences, PBC Stock Price
- MycoMedica Life Sciences, PBC Management
- Available deals in MycoMedica Life Sciences, PBC and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- MycoMedica Life Sciences, PBC Cap Table and Funding History by Share Class and Liquidity Preferences
- MycoMedica Life Sciences, PBC Revenue and Financials
- MycoMedica Life Sciences, PBC Highlights
- MycoMedica Life Sciences, PBC Business Model
- MycoMedica Life Sciences, PBC Risk Factors
- MycoMedica Life Sciences, PBC Research Report from SACRA Research
Trading MycoMedica Life Sciences, PBC Stock
How to invest in MycoMedica Life Sciences, PBC stock?
Accredited investors can buy pre-IPO stock in companies like MycoMedica Life Sciences, PBC through EquityZen funds. These investments are made available by existing MycoMedica Life Sciences, PBC shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell MycoMedica Life Sciences, PBC stock?
Shareholders can sell their MycoMedica Life Sciences, PBC stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
